Summary
The effect of zolpidem 10 mg p.o. on sleep in patients with persistent psychophysiological insomnia was assessed by polysomnographic recordings.
An improvement in sleep with no rebound insomnia was observed during treatment for two weeks. Time awake after the onset of sleep was reduced after one week and increased after two weeks, whereas sleep latency remained reduced.
Zolpidem markedly increased the duration of Stage 2 sleep without affecting either slow wave sleep or REM sleep. Subjective evaluation of improvement in sleep was well correlated with sleep laboratory findings. Zolpidem did not impair the immediate memory or psychomotor performance of patients on the morning after its administration. Side-effects during the period of drug administration included drowsiness, fatigue, headache, anxiety and irritability. They were mild or moderate and wore off soon after awakening.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akiskal HS, Lemmi H, Yerevanian B, King D, Belluomini J (1982) The utility of the REM latency test in psychiatric diagnosis: A study of 81 depressed outpatients. Psychiatry Res 7: 101–110
Arbilla S, Allen J, Wick A, Langer SZ (1986) High affinity [3H] zolpidem binding in the rat brain: An imidazopyridine with agonist properties at central benzodiazepine receptors. Eur J Pharmacol 130: 257–263
Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, Bartholini G (1986) Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol exp Ther 237: 649–658
Grünberger J (1977) Psychodiagnostik des Alkoholkranken. Methodischer Beitrag zur Bestimmung der Organizität in der Psychiatrie. Maudrich, Wien
Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6: 65–70
Kales A, Kales JD (1984) Evaluation and treatment of insomnia. Oxford University Press, New York
Monti JM (1981) Sleep laboratory and clinical studies of the effects of triazolam, flunitrazepam and flurazepam in insomniac patients. Methods Find Expt Clin Pharmacol 3: 303–326
Monti JM, Debellis J, Gratadoux E, Alterwain P, Altier H, D'Angelo L (1982) Sleep laboratory study of the effects of midazolam in insomniac patients. Eur J Clin Pharmacol 21: 479–484
Monti JM, Alterwain P, Debellis J, Altier H, Pellejero T, Monti D (1987) Short-term sleep laboratory evaluation of midazolam in chronic insomniacs. Arzneimittelforsch/Drug Res 37: 54–57
Monti JM (1988) Toward a third generation of hypnotics. In: Sauvanet JP, Langer SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York
Nicholson AN, Pascoe DA (1986) Hypnotic activity on an imidazopyridine (zolpidem). Br J Clin Pharmacol 21: 205–211
Rechtschaffen A, Kales A (1968) A manual of standardized terminology, techniques and scoring system for sleep stages in human subjects. National Institute of Health Publ. 204. US Government Printing Office, Washington DC
Roth T, Zorick F, Witting R, Roehrs T (1982) Pharmacological and medical considerations in hypnotic use. Sleep 5: S46-S52
Thénot JP, Hermann PH, Durand A, Burke JT, Allen J, Garrigau D, Vajta S, Albin H, Thébault JJ, Olive G, Warrington SJ (1988) Pharmacokinetics and metabolism of zolpidem in various animal species and humans. In: Sauvanet JP, Langer SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York
Wechsler D (1977) A manual for the Wechsler adult intelligence scale. Psychological Corporation, New York
Williams RL, Karacan I (1978) Introduction. In: Williams RL, Karacan I (eds) Sleep disorders. Diagnosis and treatment. Wiley, New York
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Monti, J.M. Effect of zolpidem on sleep in insomniac patients. Eur J Clin Pharmacol 36, 461–466 (1989). https://doi.org/10.1007/BF00558070
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558070